Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Stifel Nicolaus Downgrades Novo Nordisk A/S (NYSE:NVO) to Hold
Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...
Jim Cramer on Novo Nordisk A/S (NVO): ‘Where Are They Going To Be In The Tariffs’
We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...
Hosted on MSN7h
Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic deal
Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...
Novo Nordisk downgraded to Hold from Buy at Stifel
Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...
Novo Nordisk added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent ...
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...
Novo Nordisk A/S (NYSE:NVO): A Strong Pipeline to Aid Recovery
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
2 Important Insights From Novo Nordisk's Earnings Call
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The company recently reported positive phase 3 results for Mim8 in patients with ...